Design Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Stockholders’ Equity

(in thousands, except share data)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balance at June 30, 2026	62,580,096	$6	$537,430	$(771)	$(334,807)	$201,858
Exercises of stock options	70,990	—	277	—	—	277
Issuance of common stock in at-the-market offering, net of issuance costs	1,133,972	—	17,209	—	—	17,209
Stock-based compensation	—	—	4,051	—	—	4,051
Unrealized loss on investments	—	—	—	(911)	—	(911)
Net loss	—	—	—	—	(20,288)	(20,288)
Balance at September 30, 2026	63,785,058	$6	$558,967	$(1,682)	$(355,095)	$202,196
Balance at December 31, 2025	60,398,051	$6	$509,100	$403	$(297,006)	$212,503
Exercises of stock options	152,902	—	445	—	—	445
Issuance of common stock under employee stock purchase plan	93,583	—	464	—	—	464
Issuance of common stock in at-the-market offering, net of issuance costs	3,140,522	—	37,116	—	—	37,116
Stock-based compensation	—	—	11,842	—	—	11,842
Unrealized loss on investments	—	—	—	(2,085)	—	(2,085)
Net loss	—	—	—	—	(58,089)	(58,089)
Balance at September 30, 2026	63,785,058	$6	$558,967	$(1,682)	$(355,095)	$202,196
Balance at June 30, 2025	56,948,126	$6	$476,738	$305	$(264,012)	$213,037
Exercises of stock options	15,631	—	37	—	—	37
Stock-based compensation	—	—	3,590	—	—	3,590
Unrealized gain on investments	—	—	—	53	—	53
Net loss	—	—	—	—	(16,997)	(16,997)
Balance at September 30, 2025	56,963,757	$6	$480,365	$358	$(281,009)	$199,720
Balance at December 31, 2024	56,754,341	$6	$468,830	$475	$(227,214)	$242,097
Exercises of stock options	29,968	—	60	—	—	60
Issuance of common stock under employee stock purchase plan	179,448	—	361	—	—	361
Stock-based compensation	—	—	11,114	—	—	11,114
Unrealized loss on investments	—	—	—	(117)	—	(117)
Net loss	—	—	—	—	(53,795)	(53,795)
Balance at September 30, 2025	56,963,757	$6	$480,365	$358	$(281,009)	$199,720

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.